Experimental Autoimmune Vasculitis

An Animal Model of Anti-neutrophil Cytoplasmic Autoantibody-Associated Systemic Vasculitis

Mark A. Little,* Lucy Smyth,* Alan D. Salama,* Sripama Mukherjee,* Jennifer Smith,* Dorian Haskard,† Sussan Nourshargh,‡ H. Terence Cook,§ and Charles D. Pusey*

From the Renal Section,* Division of Medicine, the Eric Bywaters Centre for Vascular Inflammation,† and the Department of Histopathology,§ Division of Investigative Medicine, Hammersmith Hospital, Imperial College London, London; and the William Harvey Research Institute,‡ Bart’s and The London, Queen Mary’s School of Medicine and Dentistry, London, United Kingdom

The morbidity burden associated with anti-neutrophil cytoplasmic autoantibody-associated vasculitis is increasing, and many novel biological therapies are now entering the drug development pipeline. There is thus an urgent need to develop a representative animal model to facilitate testing of these agents. We previously examined the effect of antineutrophil cytoplasmic autoantibody on leukocyte-endothelial interactions in WKY rats via immunization with human myeloperoxidase. We now seek to extend this model so that all animals reliably develop crescentic glomerulonephritis and lung hemorrhage. We also wish to investigate whether there is a genetic contribution to vasculitis development in this rat strain. Using escalating doses of human myeloperoxidase, we found that a dose of 1600 μg/kg induced pauci-immune crescentic glomerulonephritis and lung hemorrhage. We also wish to investigate whether there is a genetic contribution to vasculitis development in this rat strain. Using escalating doses of human myeloperoxidase, we found that a dose of 1600 μg/kg induced pauci-immune crescentic glomerulonephritis and lung hemorrhage in all immunized animals. We also found that the addition of pertussis toxin and killed Mycobacterium tuberculosis to the adjuvant when immunizing with 400 μg/kg of myeloperoxidase resulted in crescentic glomerulonephritis and lung hemorrhage in all animals. However, when Lewis, Wistar Furth, or Brown Norway rats were immunized using a similar protocol, no animals developed hematuria or glomerulonephritis, despite having identical levels of anti-human myeloperoxidase antibodies. We conclude that, by adjusting the immunization regimen, all WKY rats immunized with myeloperoxidase develop experimental autoimmune vasculitis, thus facilitating future therapeutic studies. The resistance of Lewis rats to experimental autoimmune vasculitis provides a genetic basis for future studies of anti-myeloperoxidase antibody-associated vasculitis. (Am J Pathol 2009, 174:1212–1220; DOI: 10.2353/ajpath.2009.080458)

Small vessel systemic vasculitis is strongly associated with the presence of autoantibodies against constituents of neutrophil cytoplasmic granules (ANCAs).1,2 The two autoantigens targeted most frequently in this devastating condition are proteinase-33 and myeloperoxidase (MPO).4,5 Patients so affected may develop inflammatory necrosis of many organs, but it is pauci-immune crescentic glomerulonephritis and pulmonary hemorrhage that cause the greatest morbidity and mortality.6

There is now convincing evidence that antibodies directed against MPO are sufficient to induce vasculitis in a murine model.7 This elegant model, induced by taking high-affinity anti-MPO antibodies raised in MPO/H11002 mice and infusing them into naïve recipient mice, has facilitated study of the role of neutrophils,8 tumor necrosis factor-α,9 and complement10 in the pathogenesis of vasculitis. This field of research has progressed dramatically since this model was described. However, because the antibodies are raised in an animal that has never been exposed to the antigen before, the disease cannot be
considered representative of autoimmune vasculitis. Therefore, although this model continues to illuminate the study of vasculitis pathogenesis, additional approaches are necessary to test the efficacy of novel therapies.

In 1993, Brouwer and colleagues11 induced crescentic glomerulonephritis in Brown Norway rats by infusing a lysosomal extract directly into the renal artery of animals immunized with human MPO. Although this model was hampered by the presence of glomerular immune deposits (the human disease being pauci-immune), it sparked a number of attempts to replicate human autoimmune vasculitis in rodents (summarized in Supplemental Figure 1, see http://ajp.amipathol.org).12–16 We have previously built on this work by inducing anti-MPO antibodies in WKY rats by immunization with 400 μg/kg of human MPO.17 This inbred rat strain is known to be very susceptible to the induction of other forms of glomerulonephritis, such as experimental autoimmune glomerulonephritis.18 We demonstrated that the induced anti-MPO antibodies cross-reacted with rat neutrophils and were capable of augmenting leukocyte-endothelial interaction and inducing microvascular injury in vivo. We also found that these animals exhibited features of mild pauci-immune vasculitis, which was indistinguishable pathologically from human vasculitis, and described this as experimental autoimmune vasculitis (EAV). This model was subsequently formed according to the directives of the UK Home Office Animals (Scientific Procedures) Act, UK (1986).

Materials and Methods

Animals

We obtained WKY/NCRiBR rats from Charles River (Margate, UK). In addition, we obtained Lewis, Sprague-Dawley, and Brown Norway rats from Harlan Olac (Bicester, Oxford, UK), and Wistar Furth rats from Harlan (Indianapolis, IN). Rats were housed in cages of three to five in non specific pathogen-free conditions, with food and water available ad libitum. All animal studies were performed according to the directives of the UK Home Office Animals (Scientific Procedures) Act, UK (1986).

Immunization Regimen

Purified human MPO (Calbiochem, Merck Biosciences, Nottingham, UK) was reconstituted in sterile water for injection (500, 1000, and 2000 μg/ml for immunization of rats with 400, 800, and 1600 μg/kg, respectively) and mixed with an equal volume of complete Freund’s adjuvant (CFA) (Sigma-Aldrich, Gillingham, UK), with or without addition of killed Mycobacterium tuberculosis (4 mg/ml final concentration). Control animals received human serum albumin (HSA, 400 μg/kg) in an equal volume of CFA. In selected experiments, MPO- and HSA-immunized animals also received 400 to 800 ng of pertussis toxin (MP Biomedicals, Solon, OH) or vehicle intraperitoneally on days 0 and 2. In experiments examining alteration of the adjuvant constituents, the doses of MPO and HSA were fixed at 400 μg/kg.

Quantification of Anti-MPO Antibodies

Enzyme-Linked Immunosorbent Assay (ELISA)

Autoantibody levels in immunized rats were measured as described previously.17 Briefly, we coated 96-well plates overnight with hMPO (2 μg/ml) in carbonate buffer (pH 9.6). After washing, the serum samples (1:100) were incubated with hMPO for 60 minutes at 37°C, washed three times, and incubated with anti-rat or human IgG-alkaline phosphatase conjugate [in phosphate-buffered saline (PBS)/bovine serum albumin (BSA) 1%/0.1% Tween] for 45 minutes at 37°C. Binding was detected with p-NPP (Sigma) and optical density was quantified at 405 nm. For the purpose of determining anti-hMPO antibody titer, we performed log dilutions of serum down to 1:10,000 and defined the titer as that dilution that resulted in a 50% drop in O.D. from that obtained with saturating antibody, with use of regression analysis to estimate the titer.

Inhibition ELISA

After coating a 96-well plate with hMPO, residual binding sites on the plastic were blocked with PBS/5%/Mar- vel/1% Tween for 2 hours. We then mixed equal volumes of hMPO (in PBS/1% BSA) and serum from rats immunized with hMPO and control rats in triplicate to achieve final hMPO half-log dilutions from 0 to 30 μg/ml. We used a serum dilution from the steep component of the anti-hMPO dilution curve: 1:2000. After incubation for 2 hours, the remainder of the ELISA was performed as described above. To calculate the percent inhibition, we used the following formula19: 1 = [(S/MPO – C)/(S – C)] where, S = binding of sera from rats with EAV, S/MPO = binding of test sera after incubation with soluble hMPO, and C = binding of control sera.

Indirect Immunofluorescence

We incubated 50 μl of test serum from WKY rats immunized with MPO (EAV serum) and HSA (control serum) (all 1:20) with i) ethanol-fixed human neutrophil cyto-
spins for 30 minutes; ii) paraformaldehyde-fixed, sapo-
lin (0.0001%)-permeabilized neutrophil suspensions for 20 minutes at 4°C; or iii) ethanol-fixed WKY rat mixed peritoneal exudate cytopsins for 30 minutes. In experi-
ments using rat leukocytes, to differentiate neutrophil
from monocyte binding, we used an additional 30-minute
incubation step with mouse anti-ED1 antibody or isotype
control (1:500; Abcam, Cambridge, UK). After washing in
PBS, we incubated with secondary antibody [Alexa-568/
488-conjugated anti-rat IgG (1:200)] for 30 minutes. In
experiments using anti-ED1 staining, the cells were also
incubated with Alexa 633-conjugated anti-mouse IgG (1:50).
After washing, images were captured with a laser-
scanning confocal microscope (LSM 5 Pascal; Zeiss,
Jena, Germany).

**Western Blot**

Mixed leukocytes were prepared from WKY peripheral
blood, lysed, and run on sodium dodecyl sulfate-polyac-
rylamide gel electrophoresis under denaturing condi-
tions. The purified hMPO (50 μg/ml) used to induce EAV
and lysates of human neutrophils purified over percoll
were used as positive controls. Samples were transferred
to nitrocellulose membranes and incubated with primary
antibody (IgG preparation from rats immunized with 1600
μg/kg MPO, 1 mg/ml in PBS/BSA 1%/Tween), followed by
incubation with anti-IgG alkaline phosphatase conjugate,
with all incubations being for 60 minutes. We detected
binding using BCIP/NBT alkaline phosphatase substrate.

**Assessment of Disease Phenotype**

In all immunized animals, we collected the following data:

i) Hematuria and albuminuria. Urine was collected for
24 hours using metabolic cages and hematuria was as-
sessed by dipstick. We measured urinary albumin excre-
tion rate by Nephrat ELISA (Exocell, Philadelphia, PA).

ii) Creatinine was measured by the modified Jaffe re-
action in an autoanalyzer.

iii) Urinary and serum TNF-α and monocyte chemoat-
tractant protein-1 (MCP-1) were measured by ELISA ac-
cording to the manufacturer’s (R&D, Abingdon, UK) in-
structions. For this purpose, 2-hour urinary collections
were performed and the urine was snap-frozen in liquid
nitrogen, with storage at −80°C until analysis.

iv) Renal glomerular histology and immunofluorescence.
We used hematoxylin and eosin (H&E) and periodic acid
Schiff-stained sections to quantify focal proliferative glomer-
ulonephritis and crescentic glomerulonephritis (as defined
by the presence of at least two cell layers of proliferation
in Bowman’s space). All histopathology scoring was per-
formed without knowledge of the experimental condi-
tions. Glomeruli classified as demonstrating focal prolif-
erative glomerulonephritis often, but not always, had
evidence of fibrinoid necrosis. The presence of a cres-
cent superseded other glomerular changes; ie, if both
were present, the glomerulus was scored as crescentic.
In selected cases across all dose ranges we also quanti-
tified renal IgG deposition using immunofluorescence mi-
croscopy as described previously.17 The degree of fluo-
rescence intensity in these sections was analyzed using
Image-Pro plus image analysis software (MediaCyber-
netics, Bethesda, MD). To exclude the possibility that
renal injury occurred secondary to anti-human MPO an-
tibodies binding to MPO deposited in the glomeruli, we
performed immunohistochemical staining of renal and
splenic tissue using polyclonal rabbit anti-human MPO
(1:100; DAKO, Glostrup, Denmark) or control IgG. Bind-
ing was detected with peroxidase and diaminobenzidine
(EnVision, DAKO). Renal sections from a patient with
vasculitic crescentic glomerulonephritis were used for
comparison.

v) Tubulointerstitial nephritis (TIN). In addition to glo-
merular changes, it was appreciated in early studies of
EAV that TIN was a frequent finding. We quantified this
with a global visual analogue score (0 to 3): 0 = no TIN;
1 = a single focus of TIN; 2 = <25% of tubulointerstitium
involved; and 3 = >25% of tubulointerstitium involved.

vi) Severity of lung hemorrhage. To accurately assess
lung histology, it is necessary to intubate the trachea to
ensure full lung inflation at the time of fixation.21 We did
not do this, so it was not possible to accurately quantify
lung vasculitis, beyond general comments about the
presence or absence of intra-alveolar hemorrhage and
perivascular leukocyte cuffing. We did, however, find that
the lungs of many treated rats displayed petechiae over
their surface at the time of sacrifice. We quantified this
using a lung petechiae score (0 to 4). Because the right
lung was clearly visible without manipulation at the time of
thoracotomy, we used this lung for quantification pur-
poses: 0 = no hemorrhage; 1 = a single lesion; 2 = 2 to
5 lesions; 3 = 6 to 12 lesions; and 4 = more than 12
lesions/massive macroscopic lung hemorrhage.

**Statistical Analysis**

Changes in antibody levels across various hMPO doses
were compared using two-way analysis of variance. Vari-
ation in hematuria, albuminuria, glomerular cres-
tent score, lung hemorrhage, and TIN were assessed
using the Kruskal-Wallis test, with use of Dunn’s posthoc
test to compare individual groups. Creatinine clearance
was compared using analysis of variance, with posthoc
testing for linear trend with increasing dose of hMPO.

**Results**

**Antibody Response of WKY Rats Immunized
with hMPO: Time Course and Effect of
hMPO Dose**

All rats immunized with hMPO developed anti-hMPO an-
tibodies by day 14 after immunization (Figure 1). Using
indirect immunofluorescence on fixed human neutrophils,
sera from MPO-immunized rats exhibited a typical pe-
rinuclear pattern of binding (Figure 1A) that was indistin-
guishable from the pattern produced by serum from pa-
ients with MPO-ANCA-associated systemic vasculitis. As
shown previously, these sera cross-reacted with WKY rat neutrophils as demonstrated by indirect immunofluorescence on WKY neutrophils, Western blot (Figure 1C), and by flow cytometry (data not shown). The antibodies bound to a 55-kDa band consistent with the heavy chain of MPO. By 6 weeks, hMPO-immunized rats had anti-hMPO titers of 1:1600 by ELISA. To ensure that the results obtained with ELISA were indicative of specific anti-hMPO antibodies, we performed inhibition ELISA using escalating concentrations of soluble hMPO. This confirmed that the binding of serum to immobilized hMPO was specifically inhibited in a log-linear manner (Figure 1B). Rats immunized with HSA were negative for anti-hMPO antibodies (Figure 1D). Anti-hMPO antibody levels were significantly higher in rats immunized with 1600 μg/kg of hMPO (Figure 2A). Median titers were 1:3500 (IQR 1900 to 13000), 1:4000 (IQR 2800 to 7500), and 1:15,900 (range, 4400 to 33,000) in 400, 800, and 1600 μg/kg groups, respectively.

Phenotype of WKY Rats Immunized with hMPO: Urinary Abnormality

All rats immunized with 400 μg/kg of hMPO developed hematuria by 6 weeks and six (50%) developed proteinuria (>1 mg/24 hours, Figure 1E). Mean albumin excretion rate was significantly greater in EAV rats (8.1 ± 4.2 mg versus 0.4 ± 0.05 mg in EAV and control rats, respectively, P < 0.005; Figure 1E). None of the control rats developed hematuria. It appeared that the biggest effect of dose on urinary findings came with doubling the hMPO dose from 800 to 1600 μg/kg (Figure 2, B–F), with macroscopic hematuria (grade 4) evident in all rats immunized with the higher dose by 6 weeks after immunization. Consistent with this, there was a large increase in albuminuria in this group (mean at 6 weeks: 44.5 ± 14.1 mg/24 hours). There was a trend toward a reduction in excretory renal function with increasing doses of hMPO.
Urinary albumin excretion rate was measured with ELISA. Bars represent the mean ± SEM. **P < 0.01; ***P < 0.001.

Figure 2. Vasculitis phenotype 6 weeks after immunization with a dose range from 400 to 1600 μg/kg of hMPO or HSA in WKY rats. A: Anti-hMPO antibodies in serially diluted serum were assessed using ELISA. Bars represent the mean ± SEM. 

Phenotype of WKY Rats Immunized with hMPO: Renal Pathology

Immunization with hMPO induced focal proliferative glomerulonephritis with patchy fibrinoid necrosis and crescentic glomerulonephritis. The glomerular lesion was variable both between and within animals. The percentage of animals developing crescentic glomerulonephritis was 46%, 64%, and 100% in the groups receiving 400, 800, and 1600 μg/kg, respectively. In those animals developing crescents, the renal injury was focal (mean percentage of crescentic glomeruli 4.7 ± 2.4, 3.8 ± 2.4, and 10.5 ± 5.1% in groups receiving 400, 800, and 1600 μg/kg, respectively, Figure 2). There was minimal glomerular deposition of immunoglobulin by immunofluorescence at all doses used, as found previously and illustrated in Supplemental Figures 1 to 3, see http://ajp.amjpathol.org. hMPO deposits were detectable in kidney sections; occasional positive staining cells were evident in the spleens of both HSA and hMPO-immunized animals (Supplemental Figure 4, see http://ajp.amjpathol.org). All animals immunized with 1600 μg/kg of hMPO developed severe interstitial nephritis (TIN, Figure 2). The prominent hematuria on dipstick was reflected in the presence of numerous red cell casts, often spatially associated with injured glomeruli. No crescents were seen in control rats immunized with HSA.

Phenotype of WKY Rats Immunized with hMPO: Lung Pathology

At the time of sacrifice, 70%, 73%, and 100% of rats immunized with 400, 800, and 1600 μg/kg of hMPO, respectively, had petechiae over the surface of the lungs (Figure 3). These were bright red and macular and associated with histological evidence of alveolar hemorrhage. The macroscopic lung hemorrhage score was significantly higher in hMPO-immunized rats when compared with HSA-immunized control rats (mean 1.0 ± 0.3, 1.6 ± 0.4, 2.5 ± 0.6, and 0.4 ± 0.2 in 400 μg/kg, 800 μg/kg, 1600 μg/kg, and HSA groups, respectively; Figure 2).
phenotype of WkY rats immunized with hMPO: monocyte chemoattractant protein-1 (MCP-1) and tumor necrosis factor (TNF-α)

Levels of TNF-α were low in both serum and urine, with no difference between hMPO (400 μg/kg) and HSA-immunized animals. Mean serum TNF-α concentration was 3.3 ± 0.6 pg/ml and 3.7 ± 0.7 pg/ml in EAV and control rats, respectively. Levels in the urine were in many cases below the detection limit for the assay (0.5 pg/ml), with no difference between the experimental groups (2.9 ± 1.0 pg/mmol and 2.6 ± 1.0 pg/mmol creatinine in EAV and control rats, respectively). On the other hand, urine MCP-1 levels were relatively high, although there were again no differences between hMPO- and HSA-immunized rats (22.1 ± 3.0 ng/mmol and 25.3 ± 8.0 ng/mmol creatinine in EAV and control rats, respectively).

Addition of pertussis toxin and customization of CFA

Addition of the adjuvant pertussis toxin 200 ng i.p. to the 400 μg/kg MPO in CFA immunization regimen on days 0 and 2 increased hematuria nonsignificantly, and had no effect on albuminuria (Figure 4C). Increasing the pertussis toxin dose to two doses of 400 ng, combined with modification of CFA by addition of killed M. tuberculosis further increased hematuria to the extent that hMPO (400 μg/kg)-immunized animals had more extensive hematuria at day 28 than animals immunized with standard CFA, respectively, rats so immunized had evidence of TIN [mean TIN score 0, 1.8 ± 0.6, 1.8 ± 0.4, and 2.4 ± 0.4 in rats immunized with HSA + pertussis, hMPO + vehicle, hMPO + pertussis (400 ng), and hMPO + pertussis (800 ng) in modified CFA, respectively). P = NS].

Effect of Rat Strain on EAV Phenotype

In response to immunization with 400 μg/kg of hMPO, WKY, BN, Lewis, and WF rats all developed high levels of anti-hMPO antibodies, as measured by ELISA (Figure 5A). There were no significant differences between the four strains with respect to antibody titer. None of the strains developed anti-hMPO antibodies in response to HSA immunization. By 6 weeks after immunization, all WKY rats developed hematuria and half developed mild albuminuria (Figure 5, C and D), whereas no urinary abnormalities were seen in the other rat strains. Consistent with this, only WKY rats developed crescentic nephritis. When analyzed in a blinded manner, some BN rats were scored as having focal proliferative glomerular changes (Figure 5B). This finding was the same in hMPO and HSA groups and reflects the relatively hypercellular nature of BN glomeruli.

Discussion

Using a model of ANCA induction by immunization with hMPO (previously used to investigate the impact of this autoantibody on leukocyte-endothelial interaction), we have investigated whether increasing antigen dose or modifying immunization adjuvant can lead to a more robust representation of human vasculitis. We found that increasing hMPO antigen dose to 1600 μg/kg, or adding a combination of pertussis toxin and killed M. tuberculosis to the adjuvant, results in crescentic nephritis and lung hemorrhage in all immunized rats. Similar to human vasculitis, the pauci-immune renal disease was focal, with areas of normal kidney adjacent to severely damaged areas, and the overall fraction of glomeruli with crescents being 10 to 14%. We also investigated whether other inbred rat strains were susceptible to induction of vasculitis by immunization with hMPO. The finding of complete resistance to vasculitis in the non-WKY strains tested (despite all strains developing high titers of anti-hMPO
antibodies) paves the way for genetic studies to look for vasculitis susceptibility genes.

A dose of 10 µg (equivalent to ~80 µg/kg) of hMPO given subcutaneously to WKY rats induced anti-MPO antibodies but no vasculitis in previous studies. We have found that a much greater dose is required to induce vasculitis reliably. The renal disease in this model is characterized primarily by hematuria (as in human systemic vasculitis), although more severely affected animals developed moderate degrees of albuminuria. We were unable to demonstrate a consistent effect of vasculitis severity on urinary MCP-1 excretion, a biomarker that is under investigation in human vasculitis. This may have occurred because of the marked generalized effect of Freund’s adjuvant on macrophage function, making it impossible to differentiate MCP1 production between hMPO- and HSA-immunized animals.

The greatest effect on disease phenotype of increasing antigen dose occurred between 800 and 1600 µg/kg. That lower doses produced a very variable response suggests that these doses are on the lower part of antigen dose-response curve, and that 1600 µg/kg is near the top part of the curve. It is conceivable that further increases of dose may induce more severe disease, to the extent that excretory renal function is impaired (as seen in many cases of human vasculitis). This may have occurred because of the marked generalized effect of Freund’s adjuvant on macrophage function, making it impossible to differentiate MCP1 production between hMPO- and HSA-immunized animals.

The greatest effect on disease phenotype of increasing antigen dose occurred between 800 and 1600 µg/kg. That lower doses produced a very variable response suggests that these doses are on the lower part of antigen dose-response curve, and that 1600 µg/kg is near the top part of the curve. It is conceivable that further increases of dose may induce more severe disease, to the extent that excretory renal function is impaired (as seen in many cases of human vasculitis). Indeed, an analogous rodent model of crescentic glomerulonephritis, experimental autoimmune glomerulonephritis, is under investigation in human vasculitis. This may have occurred because of the marked generalized effect of Freund’s adjuvant on macrophage function, making it impossible to differentiate MCP1 production between hMPO- and HSA-immunized animals.

We found that, among four rat strains tested, only the WKY rat was susceptible to the induction of systemic vasculitis after immunization with hMPO in CFA. This is the first experimental demonstration of a definite genetic contribution to autoimmune anti-MPO antibody-associated vasculitis. Of particular note is the finding that resistance to disease occurred despite the induction of similar titers of ANCA. Lewis and WKY rats share the same MHC haplotype (RT1l), thus indicating that the susceptibility to EAV involves non-MHC-linked genes. Although it is possible that there was a qualitative difference between the antibody type induced in the different rat strains to account for the absence of disease despite similar titers of anti-MPO antibody (eg, variation in IgG subtype or a greater fraction of antibody reactive against rat MPO in WKY rats), we believe it is more likely that the essential functional difference between the rat strains is further downstream in the effector arm of the immune response.

For example, it has been found that WKY macrophages are much more effective at killing antibody-coated mesangial cells in vitro. Two other rodent models of crescentic nephritis, experimental autoimmune glomerulonephritis and nephrotoxic nephritis (NTN), are induced by immunization with glomerular basement membrane antigens and injection of nephrotoxic serum, respectively. Studies from our group into the genetic contribution to these models have focused on the finding that WKY rats are susceptible to disease induction, whereas Lewis rats are resistant. As with our attempts at inducing EAV in the Lewis strain, Lewis rats injected with glomerular basement membrane develop high titers of antibody but no glomerulonephritis. Genome-wide linkage analyses using various breeding strategies have

**Figure 5.** Phenotype 6 weeks after immunization with 400 µg/kg of hMPO or HSA in WKY, Brown Norway (BN), Lewis, and Wistar Furth (WF) rats. A: Anti-hMPO antibodies in serially diluted serum were measured using ELISA 6 weeks after immunization with HSA or hMPO. Each point indicates the mean ± SEM for each rat strain. B: Glomerular changes 6 weeks after immunization were assessed blindly using H&E- and periodic acid-Schiff-stained sections. Bars represent the mean ± SEM, *P < 0.05. C: Hematuria was assessed semiquantitatively with a urinary dipstick. Each data point represents an individual animal and the bars indicate the mean. D: Urinary albumin excretion rate was assessed with ELISA. Each data point represents an individual animal and the bars indicate the median. n = 4 to 5 rats in each group.
shown a significant area of linkage to glomerulonephritis susceptibility on chromosomes 13 and 16 in NTN, and we have demonstrated that Fcγ-receptor copy number underlies some of this variation in susceptibility to NTN.\textsuperscript{26} Lewis rats are also resistant to the induction of EAV, thus providing the basis for similar genetic studies. Through the use of Lewis/WKY congenic strains, it should be feasible to investigate in more depth the exact contribution of various target loci on the WKY genome to the development of EAV.

Adjuvants are crucial in animal models of autoimmunity in that most autoantigens are insufficiently potent to induce an adequate immune response on their own. Pertussis toxin is a potent immune stimulator that is used in the induction of experimental autoimmune encephalitis,\textsuperscript{31} and the \textit{M. tuberculosis} fraction of CFA, primarily by activating the innate immune system, is essential for the induction of a cell-mediated immune response.\textsuperscript{32} Use of a regimen using pertussis (400 ng on days 0 and 2), in addition to making up the hMPO antigen in CFA to which further \textit{M. tuberculosis} had been added, had the effect of inducing crescents in all animals. The severity of glomerulonephritis induced by 400 \(\mu\)g/kg of hMPO using this adjuvant was similar in magnitude to that seen after immunization with 1600 \(\mu\)g/kg of hMPO in standard CFA. Thus, this may be a more economical approach to inducing reliable disease for therapeutic studies than progressive increases in antigen dose. It is also possible that combining higher antigen doses with modification of the adjuvant may further increase disease severity.

As mortality rates have fallen with increased use of cyclophosphamide-based treatment regimens, the prevalence of ANCA-associated vasculitis in the community (with its associated morbidity burden) has increased. Much of this disease-associated morbidity is related to treatment toxicity. Therefore, it is encouraging that the last 5 years has seen a number of promising novel biological agents for treatment of this disease enter the drug development pipeline. The need for a reliable representative animal model of human autoimmune small vessel systemic vasculitis has never been more acute. Although the revised EAV model described here is not characterized by the progressive renal failure seen in human ANCA-associated vasculitis, we have demonstrated that it is possible to induce crescentic glomerulonephritis and lung hemorrhage in all WKY rats immunized with hMPO. This is of critical importance to future therapeutic studies because it allows one to markedly reduce the number of animals required to demonstrate a statistical effect of a given treatment. Our knowledge of the unique pathogenic mechanisms operating in ANCA-associated vasculitis has expanded greatly in the past 5 years. We are now in a position to begin developing novel biological agents designed to inhibit specific components of this pathogenic pathway. We believe that the revised EAV model will play an important role in such drug development.

References


